Literature DB >> 19818659

Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.

Martin Bidlingmaier1, Pamela U Freda.   

Abstract

Measuring the concentration of growth hormone (GH) in blood samples taken during dynamic tests represents the basis for diagnosis of growth hormone related disorders, namely growth hormone deficiency and growth hormone excess. Today, a wide spectrum of immunoassays are in use, enabling rapid and sensitive determination of growth hormone concentrations in routine diagnostics. From a clinical point of view several difficulties exist with the use and interpretation of GH assay results in the assessment of GH related disorders: Many physiological factors such as fat mass, age and gender influence the outcome of dynamic tests, overall leading to significant inter-individual differences in GH responses. However, in addition to the physiological variability, considerable variability exists in GH assay results obtained by different immunoassays. Unfortunately, all the new technical advances in the field of GH measurement techniques have not reduced this methodological variability. To a large extent, the actual values reported for the GH concentration in a sample depend on the method used by the respective laboratory. Obviously, such discrepancies limit the applicability of consensus guidelines on diagnosis and treatment in clinical practice. This review summarizes current practices for GH measurement with respect to the methods used, their limitations and the clinical consequences of the existing heterogeneity in GH immunoassay results. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818659      PMCID: PMC7748084          DOI: 10.1016/j.ghir.2009.09.005

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  66 in total

1.  Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones.

Authors:  M J Evans; J H Livesey; M J Ellis; T G Yandle
Journal:  Clin Biochem       Date:  2001-03       Impact factor: 3.281

Review 3.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Stephen M Shalet; Mary Lee Vance; Patricia A Stephens
Journal:  J Clin Endocrinol Metab       Date:  2006-04-24       Impact factor: 5.958

4.  Consensus statement on the standardisation of GH assays.

Authors:  Peter J Trainer; Julian Barth; Cathie Sturgeon; Gilbert Wieringaon
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

Review 5.  What endocrinologists should know about growth hormone measurements.

Authors:  Martin Bidlingmaier; Christian J Strasburger
Journal:  Endocrinol Metab Clin North Am       Date:  2007-03       Impact factor: 4.741

6.  European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency.

Authors:  Anders Juul; Sergio Bernasconi; Peter E Clayton; Wieland Kiess; Sabine DeMuinck-Keizer Schrama
Journal:  Horm Res       Date:  2002

7.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

Authors:  P J Trainer; W M Drake; L Katznelson; P U Freda; V Herman-Bonert; A J van der Lely; E V Dimaraki; P M Stewart; K E Friend; M L Vance; G M Besser; J A Scarlett; M O Thorner; C Parkinson; A Klibanski; J S Powell; A L Barkan; M C Sheppard; M Malsonado; D R Rose; D R Clemmons; G Johannsson; B A Bengtsson; S Stavrou; D L Kleinberg; D M Cook; L S Phillips; M Bidlingmaier; C J Strasburger; S Hackett; K Zib; W F Bennett; R J Davis
Journal:  N Engl J Med       Date:  2000-04-20       Impact factor: 91.245

8.  Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme.

Authors:  J Seth; A Ellis; R Al-Sadie
Journal:  Horm Res       Date:  1999

9.  Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

Authors:  P U Freda; K D Post; J S Powell; S L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

Review 10.  Growth hormone assays: current methodologies and their limitations.

Authors:  Martin Bidlingmaier; Christian J Strasburger
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

View more
  32 in total

1.  Exploiting Nanobodies in the Detection and Quantification of Human Growth Hormone via Phage-Sandwich Enzyme-Linked Immunosorbent Assay.

Authors:  Hossam Murad; Jana Mir Assaad; Rasha Al-Shemali; Abdul Qader Abbady
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-30       Impact factor: 5.555

2.  Cardiovascular endocrinology: Growth hormone in CVD prediction--a tall order?

Authors:  Connie W Tsao; Ramachandran S Vasan
Journal:  Nat Rev Endocrinol       Date:  2014-11-18       Impact factor: 43.330

3.  Harmonisation of growth hormone assays in australasia.

Authors:  James Davidson
Journal:  Clin Biochem Rev       Date:  2012-08

Review 4.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

Review 5.  Physiology and role of irisin in glucose homeostasis.

Authors:  Nikolaos Perakakis; Georgios A Triantafyllou; José Manuel Fernández-Real; Joo Young Huh; Kyung Hee Park; Jochen Seufert; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2017-02-17       Impact factor: 43.330

Review 6.  Growth hormone deficiency: optimizing therapy and new issues.

Authors:  Raphaël Rappaport
Journal:  Indian J Pediatr       Date:  2011-10-29       Impact factor: 1.967

7.  Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.

Authors:  Yasuyuki Kinoshita; Atsushi Tominaga; Satoshi Usui; Kazunori Arita; Tetsuhiko Sakoguchi; Kazuhiko Sugiyama; Kaoru Kurisu
Journal:  Neurosurg Rev       Date:  2016-01-20       Impact factor: 3.042

8.  Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.

Authors:  Giuseppe Reimondo; Marta Bondanelli; Maria Rosaria Ambrosio; Franco Grimaldi; Barbara Zaggia; Maria Chiara Zatelli; Barbara Allasino; Federica Laino; Emiliano Aroasio; Angela Termine; Pierantonio Conton; Agostino Paoletta; Ernesto Demenis; Ettore Degli Uberti; Massimo Terzolo
Journal:  Endocrine       Date:  2013-06-21       Impact factor: 3.633

Review 9.  Diagnosis of growth hormone deficiency in childhood.

Authors:  Takara Stanley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-02       Impact factor: 3.243

Review 10.  Measuring growth hormone and insulin-like growth factor-I in infants: what is normal?

Authors:  Colin Patrick Hawkes; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.